medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 4

<< Back Next >>

Rev Mex Neuroci 2008; 9 (4)

Necessity of a neuroprotective therapy in the treatment of Parkinson’s disease (PD)

Pedroso II, Aguiar RA, Bringas VML, Álvarez SM, Álvarez GL, Díaz FA, Padrón SA

Language: Spanish
References: 56
Page: 298-302
PDF size: 55.28 Kb.


ABSTRACT

PD is a neurodegenerative affection of unknown etiology related to age. Currently a combination of genetic and environmental factors that lead to the degeneration of dopaminergic nigral neurons is the considered probability. The knowledge of biochemical bases of the disease has helped to find medications that pretend to restore the function or avoid the loss of the nigrostriatal dopaminergic system. In spite of most updated therapies, our patients continue to a progressive disability. At present time the pharmacological approach is insufficient to stop the degeneration of dopaminergic neurons and to maintain the benefit of motor control. Nowadays we have the challenge to work in the development of a therapy that applied in earlier stages of PD be capable to slow down, stop or revert its clinical evolution. The clinical use of neuroprotective agents has had the obstacle of its toxicity or lack of efficacy (coenzyme Q, riluzole, selegiline, etc.). At lab studies, potential neuroprotective drugs have been obtained, but clinical markers can be confused with symptomatic markers that can be affected due to pharmacological changes and resulting pharmacodynamics. There are no drugs or therapies that totally block the progression of PD. The comprehension of responsible mechanisms of neuronal degeneration will lead to the development of neuroprotective agents.


REFERENCES

  1. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions 1. JAMA 2004 21; 291(3): 358-64.

  2. Drijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez- Pousa S. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.

  3. Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003; 529-33.

  4. Halliday GM, Heather McC. Human-based studies on α-synuclein deposition and relationship to Parkinson’s disease symptoms. Experimental Neurology 2008; 209: 12-21.

  5. Moore DJ, West AB. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci 2005; 28: 57-87.

  6. Braak H, Del Tredeci K, Rub U. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.

  7. Long A, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-16.

  8. Morrish PK, Rakshi JS, Bailey DL. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.

  9. Kieburtz KM. Issues in neuroprotection clinical trials in Parkinson’s disease. [Article]. Neurology New Approaches to Neuroprotective Therapy in Parkinson’s Disease 2006; 66(10): S50-S57.

  10. Macphee GJ, Stewart DA. Parkinson’s disease. [Miscellaneous Article]. Reviews in Clinical Gerontology 2006; 16(1): 1-21.

  11. Olanow CW, Schapira AH. Neuroprotection for Parkinson’s disease: Prospects and Promises. Annals of Neurology 2003; 53(Suppl. 3): S1-S2.

  12. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y. Decreased single-photon emission computed tomographic [123I]beta- CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 1995; 38: 589-98.

  13. Suchowersky OM, Gronseth GM, Perlmutter JM, Reich SM, Zesiewicz TM, Weiner WJM. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. [Article]. Neurology 2006; 66(7): 976-82.

  14. Rascol O, Payoux P, Ory F. Limitations of current Parkinson’s disease therapy. Ann Neurol 2003; 53: S3-S15.

  15. Bonuccelli UM, Del Dotto PM. New pharmacologic horizons in the treatment of Parkinson disease. [Article]. Neurology Present and Future Approaches to Parkinson Disease: From Molecular Insights to New Therapeutic Avenues 2006; 67(7): S30-S38.

  16. Litvan IM, Chesselet M-FMP, Gasser TM, Di Monte DAM, Parker DJ, Hagg TM, et al. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. [Review]. Journal of Neuropathology & Experimental Neurology 2007; 66(5): 329-36.

  17. Lin JJ, Yueh KC, Chang CY, Chen CH, Lin SZ. The homozygote AA genotype of the [alpha]1-antichymotrypsin gene may confer protection against early-onset Parkinson’s disease in women. Parkinsonism & Related Disorders 2004; 10(8): 469-73.

  18. Foltynie T, Sawcer S, Brayne C, Barker RA. The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73: 363-70.

  19. Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: a review. Ann Hum Genet 2001; 65(111): 126.

  20. Pezzoli G, Strada O, Silani V. Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann Neurol 1996; 40: 922-5.

  21. Twelves D, Perkins KS, Perkins KS. Systematic review of incidence studies of Parkinson’s disease. Mov Disord 2003; 18: 19-31.

  22. Barbeau A, Roy M, Bernier G. Ecogenetics of Parkinson’s disease: prevalence and environmental aspects of rural areas. Can J Neurol Sci 1987; 14: 36-41.

  23. Gorrell JM, Di Monte D, Graham D. The role of the environment in Parkinson’s disease. Environ Health Perspect 1996; 104: 652-4.

  24. Fall PA, Fredrikson M, Axelson O. Nutritional and occupational factors influencing the risk of Parkinson’s disease: a case-control study of southeastern Sweden. Mov Disord 1999; 14: 28-37.

  25. Semchuk KM, Love EJ, Lee RG. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42: 1328-35.

  26. Seidler A, Hellenbrand W, Robra BP. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 1996; 46: 1275-84.

  27. Semchuk KM, Lee RF. Parkinson’s disease and exposure to rural environmental factors: a population based casecontrol study. Can J Neurol Sci 1991; 18: 279-86.

  28. Koller W, Vetere-Overfield B, Gray C. Environmental risk factors in Parkinson’s disease. Neurology 1990; (40): 1218-21.

  29. Jenner P. Parkinson’s disease, pesticides and mitochondrial dysfunction. Trends Neurosci 2001; 24: 245-7.

  30. Foley P, Riederer P. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease. J Neurol 2000; 247: 82-94.

  31. Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3: 932-42.

  32. Von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson’s disease. Progr Neurobiol 2004; 73: 151-77.

  33. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003; 53: S26-S36.

  34. Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000; 275: 35661-4.

  35. Nishikawa K, Li H, Kawamura R. Alterations of structure and hydrolase activity of parkinsonism associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 2003; 304: 176-83.

  36. Elbaz A, Levecque C, Clavel J. S18Y polymorphism in the UCH-L1 gene and Parkinson’s disease: evidence for an age-dependent relationship. Mov Disord 2003; 18: 130-7.

  37. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitin proteasomal pathway in Parkinson’s disease and other neurodegenerative disorders. Trends Neurosci 2001; 24(S7): S14.

  38. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 2003; 53(Suppl. 3): S49-S60.

  39. Schapira AH. Dopamine agonists and neuroprotection in Parkinson’s disease. Eur J Neurol 2002; 9(Suppl. 3): 7-11.

  40. Tatton WG, Chalmers-Redman R, Brown D, Taton N. Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann Neurol 2003; 53(Suppl. 3): S61-S72.

  41. Goetz C, Koller WC, Poewe O. Manageent of Parkinson’s disease: an evidence-based review. Mov Disord 2002; 17(Suppl. 4): S1-S166.

  42. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364-71.

  43. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993; 328: 176-83.

  44. LeWitt PA. Clinical trials of neuroprotection for Parkinson’s disease. Neurology 2004; 63(Suppl. 2): S23-S31.

  45. Beal MF, Matthews RT, Tieliman A. Coenzyme Q10 attenuates the 1- methyl-4-phinyl-1,2,3,tetrahydro-pyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998; 783: 109-14.

  46. Shults CW, Oakes D, Kieburtz KM, Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson’s disease: evidence for slowing of the function decline. Arch Neurol 2002; 59: 1541-50.

  47. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 271-6.

  48. Rascol O, Olanow W, Brooks D, Brooks D, Truffinet P, Bejuit R, et al. Effect of riluzole on Parkinson’s disease progression: a double-blind placebo-controlled study. Neurology 2003; 60(Suppl. 1): A288.

  49. Pan TH. Biological effects of pramipexole on dopaminergic neuronassociated genes: relevance to neuroprotection. Neurosci Lett 2008; [In press].

  50. Olanow CW, Freeman TB, Kordower JH. Fetal nigral transplantation as a therapy for Parkinson’s disease. Trends Neurosci 1996; 19: 102-9.

  51. Freed CR, Greene PE, Breeze RE. Embryonic dopaminergic tissue transplants in advanced Parkinson’s disease. N Engl J Med 2001; 344: 710-9.

  52. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson’s disease? Drug Aging 2001; 18: 389-96.

  53. Nutt JG, Burchiel KJ, Comella CL. ICV GDNF Study Group. Randomized double-blind trial of glial cell line-derived neurotrophic factors (GDNF) in PD. Neurology 2003; 60: 69-73.

  54. Annett LE, Martel FL, Rogers DC, Ridley RM, Baker HF, Dunnett SB. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 1994; 125(2): 228-46.

  55. Whone AL, Watts RL, Stoessl AJ. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.

  56. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.




2020     |     www.medigraphic.com